Advanced search×

A novel therapeutic option in Cogan diseases? TNF-alpha blockers.

M M Fricker, A A Baumann, F F Wermelinger, P M PM Villiger, and A A Helbling

Rheumatol Int 27(5):493-5 (2007) PMID 17102947

Cogan's syndrome is characterized by noninfectious, interstitial keratitis combined with a vestibulo-auditory deficit. Despite therapy with corticosteroids in combination with immunosuppressive agents, relapses occurred in two subjects and the clinical course suggested a progression of the disease. Treatment with anti-TNF-alpha was started leading to a rapid and sustained clinical remission for over 2 respectively 3 years.

DOI: 10.1007/s00296-006-0252-y
Version: za2963e q8zae q8zb5 q8zcb q8zdc q8ze9 q8zfc q8zg6
Buy PDF

Similar articles you may find interesting…

  1. Characteristics of Children with Non-Hodgkin Lymphoma Associated with Primary Immune Deficiency Diseases: Descriptions of Five Patients.
    Suna Emir, Emine Vezir, and Ayşe Metin

    Pediatr Hematol Oncol (2013) PMID 23647505

    All patients were male (median age, 8 years). Stage distribution was stage III in three patients and stage IV in two patients. Three patients had B-cell lymphoma and two had T-cell lymphoma. Reduced doses of Berlin-Frankfurt-Münster (BFM) and French Society of Pediatric Oncology (SFOP) regimens we...
    Buy PDF
  2. Canakinumab: A Guide to Its Use in Acute Gouty Arthritis Flares.
    Katherine A Lyseng-Williamson

    BioDrugs (2013) PMID 23649936

    Canakinumab (Ilaris(®)), an anti-interleukin-1β monoclonal antibody, is a novel approach to treat acute gouty arthritis flares in a targeted population of patients in whom treatment options are limited. Relative to on-demand treatment with intramuscular triamcinolone acetonide 40 ...
    Buy PDF
  3. Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid Leukemia-a wise liaison?
    U Platzbecker and U Germing

    Leukemia (2013) PMID 23644421

    Treatment options for older patients with advanced myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) are limited and the prognosis remains poor, thereby warranting development of novel therapies. Aberrant epigenetic modifications, including altered DNA methylation, seem...
    Buy PDF